Immune Complex-Mediated Glomerulonephritis: Diagnosis, Differential Diagnosis, and Management
Diagnosis
The diagnosis of immune complex-mediated GN requires kidney biopsy with immunofluorescence microscopy showing positive immunoglobulin deposition (with or without complement), which directs the workup toward distinguishing between monoclonal deposition diseases, autoimmune diseases, and infection-associated diseases. 1
Essential Diagnostic Steps
- Kidney biopsy is mandatory and remains the gold standard for diagnosis, as it is the only method to identify IC-MPGN and distinguish it from complement-mediated diseases like C3 glomerulopathy 2, 3
- Immunofluorescence findings guide the diagnostic pathway: If positive for immunoglobulins (with or without complement), focus on distinguishing between monoclonal deposition diseases, autoimmune IC diseases, and infection-associated diseases 1
- Serum and urine studies must include: serum creatinine, urinalysis with quantification of proteinuria (24-hour or protein-to-creatinine ratio), complement levels (C3 and C4), protein electrophoresis with immunofixation, and free light chain analysis 4, 5
- Serologic testing should include: antinuclear antibody, anti-double stranded DNA, ANCA (anti-MPO and anti-PR3), hepatitis B and C serologies, cryoglobulin titers, and HIV testing 1, 5
- Screen for infections including viral (hepatitis C, hepatitis B, HIV), bacterial (endocarditis, infected shunts, visceral abscesses), and protozoal causes before initiating immunosuppression 1, 4
- Evaluate for autoimmune diseases including SLE, Sjögren's syndrome, rheumatoid arthritis, and mixed connective tissue disease 1
- Screen for monoclonal gammopathies with serum and urine electrophoresis, immunofixation, and free light chain analysis when monoclonal immunoglobulin deposits are found 4
- Patients ≥50 years with C3 glomerulopathy pattern should be evaluated for monoclonal proteins, as monoclonal gammopathies can initiate C3G without glomerular immunoglobulin deposition 1, 4
- Comprehensive complement analysis should be performed even in the absence of hypocomplementemia to assist with diagnosis 4
Histologic Patterns
- Membranoproliferative pattern shows mesangial and/or endocapillary hypercellularity with thickening of capillary walls caused by subendothelial deposits, with lobular accentuation and GBM double contours ("tram-tracking") 6, 5
- Document the percentage of globally sclerosed glomeruli and extent of tubulointerstitial fibrosis, as these determine chronicity and prognosis 6, 5
Critical Diagnostic Pitfall
- Proteolytic digestion on paraffin-embedded tissue may be necessary to detect monoclonal immunoglobulins masked during routine immunofluorescence investigation 1
- Complement dysregulation may occur in IC glomerular diseases, and conversely C3G may appear as ICGN, especially if triggered by infection—therefore exclude complement-mediated processes before diagnosing idiopathic ICGN 1
Differential Diagnosis
In adults, idiopathic immune complex glomerulonephritis is rare, and all other diagnostic possibilities must be exhausted before making this diagnosis. 1
Infection-Related IC-GN
- Viral causes: Hepatitis C (including HCV-associated mixed cryoglobulinemia), hepatitis B, HIV 1
- Bacterial causes: Endocarditis, infected ventriculo-atrial shunt, visceral abscesses, leprosy, meningococcal meningitis 1
- Protozoal/other infections: Malaria, schistosomiasis, mycoplasma, leishmaniasis, filariasis, histoplasmosis 1
Autoimmune IC-GN
- Systemic lupus erythematosus (lupus nephritis) 1
- Sjögren's syndrome 1
- Rheumatoid arthritis 1
- Mixed connective tissue disease 1
- Lupus-like glomerulonephritis: Pattern with IgG, IgA, IgM, C3, and C1q deposition in patients who fail to meet ACR criteria for SLE 7
Monoclonal Immunoglobulin-Related GN
- Monoclonal gammopathy due to plasma cell or B cell disorders 1
- Fibrillary glomerulonephritis 1
- Waldenström macroglobulinemia with cryoglobulin-like deposits 6
Complement-Mediated Diseases (Must Exclude)
- C3 glomerulopathy (C3 GN or dense deposit disease) if immunofluorescence shows complement-dominant pattern 1
- C4 glomerulopathy 1
Other Considerations
Management
Treatment for immune complex-mediated GN must be tailored to the underlying etiology: infection-associated diseases generally respond to controlling the infection, autoimmune diseases require immunosuppression, and monoclonal immunoglobulin-associated diseases require B or plasma cell clone-directed therapy. 1, 8
Treatment Algorithm Based on Etiology and Severity
For Infection-Related IC-GN
- Hepatitis C-associated ICGN with indolent disease: Treat with direct-acting antivirals (DAAs) alone without dose adjustment as first-line therapy 4
- HCV-associated ICGN with nephrotic syndrome but stable kidney function: Use DAAs prior to other treatments 4
- HCV-associated ICGN with rapidly progressive GN or cryoglobulinemic flare: Initiate combined therapy with DAAs plus immunosuppressive agents with or without plasma exchange 4, 9
- HCV-associated ICGN with persistent disease despite DAA therapy: Use rituximab as first-line immunosuppressive agent 4
- Non-HCV infection-related GN: Treat the underlying infection (bacterial endocarditis, cellulitis, etc.) as primary therapy 5
For Autoimmune IC-GN
- Lupus nephritis: Follow ISN/RPS classification-based treatment protocols with immunosuppression 6
- Other autoimmune diseases: Treat with immunosuppression targeting the underlying autoimmune process 1
For Monoclonal Immunoglobulin-Related GN
- Focus on controlling the B cell or plasma cell clone responsible for monoclonal immunoglobulin production 1
- Treat underlying hematologic disorder (e.g., Waldenström macroglobulinemia) 5
For Idiopathic IC-GN (After Excluding All Secondary Causes)
The approach to idiopathic ICGN is nuanced and tailored to disease severity, with restraint in aggressive treatment for patients with chronic disease. 1
Indolent Disease
- Provide supportive therapy with RAS inhibition alone for patients with non-nephrotic proteinuria and stable kidney function 4
- Monitor closely every 3-4 months with renal function, proteinuria, and urine microscopy 5
Moderate Disease (Nephrotic Syndrome with Stable Function)
- Consider oral cyclophosphamide or mycophenolate mofetil (MMF) plus low-dose alternate-day or daily corticosteroids for less than 6 months 5
- Mycophenolic acid can be considered as a cost-effective substitute for MMF in healthcare systems where coverage differs 4
Severe Disease (Rapidly Progressive GN or Crescentic GN)
- Non-HCV related cases with severe presentation: Use cyclophosphamide and corticosteroids plus plasmapheresis 4
- For rapidly progressive disease: Consider combination of two pulses of intravenous cyclophosphamide with rituximab 9
Pediatric Patients
- Alternate-day prednisone (40 mg/m²) for 6 to 12 months as first-line treatment for children with MPGN pattern and nephrotic syndrome and/or impaired renal function 5
Contraindications to Immunosuppression
Do not treat with immunosuppression in the following scenarios: 5
- Normal eGFR with non-nephrotic-range proteinuria
- Advanced CKD with severe tubulointerstitial fibrosis
- Small kidney size
- Chronic inactive disease on biopsy
Supportive Care (All Patients)
- Blood pressure control: Use ACE inhibitors or ARBs at maximum tolerated doses as first-line therapy, targeting systolic BP <120 mmHg 9
- Edema management: Sodium restriction and diuretics as first-line agents 9
- Anticoagulation consideration: Patients with nephrotic syndrome have 29% incidence of renal vein thrombosis and 17-28% incidence of pulmonary embolism due to loss of anticoagulant proteins 5
Monitoring and Follow-Up
- Regular assessment of proteinuria and surveillance for ≥40% decline in GFR from baseline over 2-3 years as surrogate outcomes for kidney failure 9
- Safety monitoring for immunosuppression: Screen for latent infections, monitor therapeutic drug levels, review vaccination status, and consider fertility preservation 9
Critical Management Pitfalls to Avoid
- Failing to distinguish primary from secondary MPGN leads to inappropriate treatment 5
- Not recognizing MPGN pattern without immune deposits (which would be complement-mediated, not IC-mediated) 5
- Treating patients with advanced chronic disease with immunosuppression is contraindicated 5
- Delaying treatment while awaiting biopsy in patients with clinical presentation compatible with rapidly progressive GN and positive serologies 9
- Limited access to plasmapheresis should be factored into urgency of diagnostic workup 4